ionsource.com valuation and analysis
Robots.txt Information
| Robot | Path | Permission |
| GoogleBot | / | ✔ |
| BingBot | / | ✔ |
| BaiduSpider | / | ✔ |
| YandexBot | / | ✔ |
Meta Tags
| Title | Mass Spectrometry |
| Description | A mass spectrometry resource web site, featured are mass spectrometry |
| Keywords | mass spectrometry, MS, mass spectrometer, Mass Spec, PTM, MS protein identification, MS quantitation, de novo peptide, capillary HPLC, proteomics, mass spectrometry standards |
Server Information
| WebSite | |
| Host IP | 66.96.146.102 |
| Location | United States |
Related Websites
| Site | Rank |
More to Explore
ionsource.com Valuation
|
US$7,993,378
Last updated: 2023-04-29 12:12:17
ionsource.com has Semrush global rank of 1,324,134. ionsource.com has an estimated worth of US$ 7,993,378, based on its estimated Ads revenue. ionsource.com receives approximately 922,313 unique visitors each day. Its web server is located in United States, with IP address 66.96.146.102. According to SiteAdvisor, ionsource.com is safe to visit. |
Traffic & Worth Estimates
| Purchase/Sale Value | US$7,993,378 |
| Daily Ads Revenue | US$7,379 |
| Monthly Ads Revenue | US$221,356 |
| Yearly Ads Revenue | US$2,656,261 |
| Daily Unique Visitors | 61,488 |
| Note: All traffic and earnings values are estimates. | |
DNS Records
| Host | Type | TTL | Data |
| ionsource.com. | A | 3599 | IP: 66.96.146.102 |
| ionsource.com. | NS | 3600 | NS Record: ns2.verio.com. |
| ionsource.com. | NS | 3600 | NS Record: ns1.verio.com. |
| ionsource.com. | MX | 3600 | MX Record: 30 mx.ionsource.com. |
| ionsource.com. | TXT | 3600 | TXT Record: v=spf1 ip4:66.96.128.0/18 ?all |
HtmlToTextCheckTime:2023-04-29 12:12:17
| Current Mass Spectrometry, Biotech, and Pharma News Bruker Signs Agreement to Acquire Oncovision’s Preclinical PET Imaging Business (09/07) Pfizer Appoints Chief Scientific Officer for Neuroscience Research (09/07) FDA Accepts SPLA, Assigns Priority Review and Grants Breakthrough Therapy Designation to Merck’s KEYTRUDA (pembrolizumab) for First-Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer (09/07) Sangamo BioSciences Receives Orphan Drug Designation From The FDA For SB-FIX, The First Application Of Therapeutic In Vivo Genome Editing (09/06) FDA Approves BLINCYTO (blinatumomab) For Use In Pediatric Patients With Philadelphia Chromosome-Negative Relapsed Or Refractory B-cell Precursor Acute Lymphoblastic Leukemia (09/01) Bruker MassSpectator, Issue 72, September 2016 (09/01) Phase III study showed Roche’s cancer immunotherapy TECENTRIQ (atezolizumab) helped people with a specific type of lung cancer live significantly longer compared to chemotherapy (09/01) (See |
HTTP Headers
HTTP/1.1 200 OK Date: Fri, 22 Oct 2021 10:02:20 GMT Content-Type: text/html Content-Length: 36707 Connection: keep-alive Server: Apache/2 Last-Modified: Sun, 16 Oct 2016 14:43:42 GMT Accept-Ranges: bytes Cache-Control: max-age=3600 Etag: "8f63-53efc7c5fadcf" Expires: Fri, 22 Oct 2021 11:02:20 GMT Age: 0 |
ionsource.com Whois Information
Domain Name: IONSOURCE.COM Registry Domain ID: 2779843_DOMAIN_COM-VRSN Registrar WHOIS Server: whois.networksolutions.com Registrar URL: http://networksolutions.com Updated Date: 2019-12-16T00:35:38Z Creation Date: 1998-12-16T05:00:00Z Registry Expiry Date: 2029-12-15T05:00:00Z Registrar: Network Solutions, LLC Registrar IANA ID: 2 Registrar Abuse Contact Email: abuse@web.com Registrar Abuse Contact Phone: +1.8003337680 Domain Status: clientTransferProhibited https://icann.org/epp#clientTransferProhibited Name Server: NS1.VERIO.COM Name Server: NS2.VERIO.COM DNSSEC: unsigned >>> Last update of whois database: 2021-09-11T01:34:58Z <<< |